Mitochondrial dysfunction plays a critical role in the development of type 2 diabetes and insulin resistance. Insulin resistance is a key factor in the pathogenesis of the metabolic syndrome and type 2 diabetes, and its mechanisms are not fully understood. Magnetic resonance spectroscopy studies suggest that the primary metabolic abnormality in insulin-resistant patients with type 2 diabetes is a defect in insulin-stimulated glucose transport in skeletal muscle. Fatty acids inhibit insulin-stimulated tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and IRS-1-associated phosphatidylinositol 3-kinase activity, contributing to insulin resistance. Several metabolic abnormalities, including increased fat delivery to muscle and liver, and defects in mitochondrial fatty acid oxidation, may increase intramycellular and intrahepatic fatty acid metabolites, leading to insulin resistance. Insulin resistance in the offspring of parents with type 2 diabetes is a strong predictor of later diabetes development. Fat-induced insulin resistance in humans is associated with increased plasma free fatty acid concentrations, which inhibit glucose transport or phosphorylation activity. This leads to reduced insulin-stimulated muscle glycogen synthesis and whole-body glucose oxidation. The reduction in glucose transport activity may be due to direct effects of fatty acids on the GLUT4 transporter or alterations in upstream insulin signaling events. Fatty acids can also activate a serine kinase cascade, leading to serine phosphorylation of IRS-1 and impairing its ability to activate PI3-kinase, thus reducing glucose transport. Increased energy intake and obesity lead to accumulation of fatty acid metabolites in muscle and liver, contributing to insulin resistance. Defects in adipocyte fatty acid metabolism, such as those seen in lipodystrophy, also contribute to insulin resistance. Mitochondrial dysfunction, whether inherited or acquired, can lead to intracellular accumulation of fatty acid metabolites, further contributing to insulin resistance. Exercise and moderate weight reduction can improve insulin sensitivity by reducing intracellular fatty acid metabolites and redistributing fat to adipocytes. Pharmacologic treatments, such as metformin and thiazolidinediones, can improve insulin sensitivity by reducing glucose production and enhancing insulin signaling. Understanding these mechanisms is crucial for developing new therapeutic targets for the prevention and treatment of type 2 diabetes.Mitochondrial dysfunction plays a critical role in the development of type 2 diabetes and insulin resistance. Insulin resistance is a key factor in the pathogenesis of the metabolic syndrome and type 2 diabetes, and its mechanisms are not fully understood. Magnetic resonance spectroscopy studies suggest that the primary metabolic abnormality in insulin-resistant patients with type 2 diabetes is a defect in insulin-stimulated glucose transport in skeletal muscle. Fatty acids inhibit insulin-stimulated tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and IRS-1-associated phosphatidylinositol 3-kinase activity, contributing to insulin resistance. Several metabolic abnormalities, including increased fat delivery to muscle and liver, and defects in mitochondrial fatty acid oxidation, may increase intramycellular and intrahepatic fatty acid metabolites, leading to insulin resistance. Insulin resistance in the offspring of parents with type 2 diabetes is a strong predictor of later diabetes development. Fat-induced insulin resistance in humans is associated with increased plasma free fatty acid concentrations, which inhibit glucose transport or phosphorylation activity. This leads to reduced insulin-stimulated muscle glycogen synthesis and whole-body glucose oxidation. The reduction in glucose transport activity may be due to direct effects of fatty acids on the GLUT4 transporter or alterations in upstream insulin signaling events. Fatty acids can also activate a serine kinase cascade, leading to serine phosphorylation of IRS-1 and impairing its ability to activate PI3-kinase, thus reducing glucose transport. Increased energy intake and obesity lead to accumulation of fatty acid metabolites in muscle and liver, contributing to insulin resistance. Defects in adipocyte fatty acid metabolism, such as those seen in lipodystrophy, also contribute to insulin resistance. Mitochondrial dysfunction, whether inherited or acquired, can lead to intracellular accumulation of fatty acid metabolites, further contributing to insulin resistance. Exercise and moderate weight reduction can improve insulin sensitivity by reducing intracellular fatty acid metabolites and redistributing fat to adipocytes. Pharmacologic treatments, such as metformin and thiazolidinediones, can improve insulin sensitivity by reducing glucose production and enhancing insulin signaling. Understanding these mechanisms is crucial for developing new therapeutic targets for the prevention and treatment of type 2 diabetes.